European Organisation For Research And Treatment Of Cancer

• Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemo… Pending
  2023-508658-24-00 Phase II 4 countries
• A phase III study on using immunotherapy and radiotherapy to treat limited spread of Head and Neck Cancer Recruiting
  2023-504478-39-00 Phase III 3 countries
• A study to test the effect of chemotherapy before surgery compared to surgery alone in patients with high risk retroperitoneal sarcoma. Recruiting
  2023-505261-84-00 Phase III 10 countries
• EORTC 2022-MG: Treatment with tebentafusp or observation for patients with melanoma of the eye after surgery or radiation (ATOM Trial) Recruiting
  2023-510333-28-00 Phase III 9 countries TEBENTAFUSP
• EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting
  2023-506817-23-01 Phase III 9 countries
• Efecto de la inmunoterapia en pacientes con cáncer de pulmón de células no pequeñas oligometastásico (número limitado de metástasis) después… Recruiting
  2023-508741-40-00 Phase II/III 5 countries
• ​​Lomustine with or without a second round of brain radiation for the reappearance of glioblastoma Recruiting
  2023-505267-36-00 Phase III 10 countries
• An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting
  2022-501453-36-00 Phase III 11 countries
• EORTC 1820-CLTF: Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam th… Recruiting
  2022-502434-10-00 Phase II 6 countries
• EORTC 1740: Randomized Phase II study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab ver… Ended
  2023-508853-13-00 Phase II 3 countries DURVALUMAB
• EORTC-1537-LYMG: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study Ended
  2023-508478-27-00 Phase II 7 countries BRENTUXIMAB VEDOTIN
• A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk… Ended
  2023-505223-31-00 Phase II 7 countries PALBOCICLIB
• Immunotherapy with ipilimumab and nivolumab preceded or not by a targeted therapy with encorafenib and binimetinib Ended
  2023-505376-30-00 Phase II 6 countries BINIMETINIB; ENCORAFENIB; IPILIMUMAB; NIVOLUMAB
• Darolutamide vs ADT in hormone naïve Pca Ended
  2024-510840-30-00 Phase II 4 countries DAROLUTAMIDE
• A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly sympto… Ended
  2023-510453-41-00 Phase III 8 countries ENZALUTAMIDE; RADIUM RA 223 DICHLORIDE
• Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck cancer Ended
  2022-502339-20-00 Phase II 9 countries XEVINAPANT
• Trial investigating a personalized treatment, based on age and tumor characteristics , of newly diagnosed medullablastoma in patients that a… Ended
  2023-506193-12-00 Phase II 1 country SONIDEGIB

Showing 1–17 of 17 trials